Other molecular alterations included mutations in the TP53, ATRX, PIK3CA, PIK3CB, PTEN genes, and CDKN2A deletion, which have been found to be specific to low-grade gliomas [27,42]. This evidence concerns the gene CDKN2A and central nervous system cancer.